Prospective Observational Study of Febrile Neutropenia (FN) and Pegfilgrastim Primary Prophylaxis in Breast Cancer and Non-Hodgkin's Lymphoma Patients Receiving High (>20%) FN-risk Chemotherapy
Phase of Trial: Phase IV
Latest Information Update: 23 Oct 2018
Price : $35 *
At a glance
- Drugs Pegfilgrastim (Primary)
- Indications Febrile neutropenia
- Focus Therapeutic Use
- Acronyms PROTECT
- Sponsors Amgen
- 31 Aug 2018 Biomarkers information updated
- 17 Nov 2016 Status changed from active, no longer recruiting to completed.
- 23 May 2016 Planned End Date changed from 1 Jan 2017 to 1 Oct 2018.